Sanofi to buy US biopharma group Blueprint for up to $9.5 billion
PARIS, June 2 (Reuters) - France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in rare immunology diseases, in the biggest deal struck by a European healthcare company so far this year, according to LSEG data.
Blueprint (BPMC.O), opens new tab is a specialist in treatments for systemic mastocytosis, a rare blood disorder.
Sign up here.
The two companies said on Monday that Sanofi (SASY.PA), opens new tab would initially pay $129.00 per share in cash, or around $9.1 billion. Blueprint shares jumped 27% to $128.74 in premarket trade. Sanofi stock was down about 1%.
Sanofi has ramped up research and development spending in recent years, prompting the company to abandon its long-term profit margin targets two years ago, as it seeks to build on the success of its blockbuster drug Dupixent for eczema and other conditions.
However, it suffered a setback last week after an experimental drug for patients with a lung condition commonly called "smoker's lung" failed a late-stage trial.
The Blueprint acquisition "represents a strategic step forward in our rare and immunology portfolios. It enhances our pipeline and accelerates our transformation into the world's leading immunology company," said Sanofi CEO Paul Hudson.
The deal would add to Sanofi's portfolio the rare immunology disease drug Ayvakit, also known as Ayvakyt, approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline.
Ayvakit is the only approved medicine for advanced and indolent systemic mastocytosis, a rare blood disorder that occurs when the body makes abnormal mast cells - a type of white blood cell. It triggers a continuous allergic response.
The acquisition would also bring elenestinib, a next-generation medicine for systemic mastocytosis, as well as BLU-808, a highly selective and potent oral wild-type KIT inhibitor that has the potential to treat a broad range of diseases in immunology.
The deal makes "strategic and financial sense", said JP Morgan analysts in a note, noting that Blueprint expects Ayvakit to reach annual sales of around $2 billion by fiscal year 2030.
"We see the transaction as a good fit for Sanofi at a sensible valuation, which investors should see as a positive with time," they added.
It is the latest in a series of deals by Sanofi. Last month, it announced the $470 million purchase of Vigil Neuroscience (VIGL.O), opens new tab and in January 2024 it struck a $2.2 billion deal for U.S biotech firm Inhibrx.
Hudson said the deal complemented Sanofi's recent acquisitions of other early-stage medicines and added that it still retained a sizable capacity for further deals.
The company has said it plans to invest at least $20 billion in the United States through 2030 to boost manufacturing and research, joining other drugmakers in responding to President Donald Trump's drive to boost local manufacturing.
Besides $129.00 per share in cash, Blueprint shareholders would also receive one non-tradeable contingent value right (CVR) per share, which would entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808.
The total equity value of the transaction, including potential CVR payments, is $9.5 billion on a fully diluted basis. It is expected to close in the third quarter, pending regulatory and shareholder approvals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
31 minutes ago
- Reuters
UK new car sales recover in May as EV discounts attract buyers, SMMT data shows
June 5 (Reuters) - Britain's new car sales rose from a year earlier in May, marking the second month of recovery in 2025, amid heavy discounting by electric vehicle makers, a report by the Society of Motor Manufacturers and Traders (SMMT) showed on Thursday. Chinese EVs have been rapidly expanding in the European markets by offering deep discounts and forcing other automakers in an intense price war that has strained their profit margins. New car registrations rose 1.6% year-over-year to 150,070 units during the month, SMMT said, the best May performance since 2021. Electric vehicles accounted for more than 47% of the total car sales in May with battery electric vehicle sales rising 25.8% year-over-year. "A return to growth for new car registrations in May is welcome but manufacturer discounting on new products continues to underpin the market, notably for electric vehicles," SMMT chief Mike Hawes said in a statement. The auto industry, already strained by supply chain disruptions and stiff competition, has been forced to cut prices amid brittle consumer sentiment, uncertain global trade policies, and the costly shift away from internal combustion engines. "The continued rise in EV registrations shows a growing consumer appetite for sustainable transport, further fuelled by the government's recent announcement to remove the need for planning applications for at home EV charging installations," said Jamie Hamilton, automotive partner and head of electric vehicles at Deloitte. Tesla (TSLA.O), opens new tab sold 2,016 cars in the UK during the month, a 36.04% decline year-over-year, according to SMMT. Data published earlier this week by research group New AutoMotive showed a bigger 45% drop in the automaker's UK sales.
Daily Mail
33 minutes ago
- Daily Mail
The BEST aftershaves at The Perfume Shop that make perfect Father's Day gifts that are up to 50% off right now - from Hugo Boss to Jean Paul Gaultier
Those looking for Father's Day gift ideas should hot-foot it to The Perfume Shop, where the brand has up to 50 per cent off fragrances for him. Father's Day can be a great opportunity to spoil them with something they wouldn't traditionally spend money on, and fragrance is top of the list. And, with over 130 perfumes for men and women, The Perfume Shop is a savvy place to start. The UK's largest perfume retailer with a list of luxury fragrance, ranging from Dior to Hugo Boss, Chanel and Tom Ford, you're sure to find their go-to fragrance or discover a new one. Better still, The Perfume Shop have launched its Father's Day gifting campaign with offers running until 9am on June 16. With up to 50 per cent off bestsellers and half price engraving from 9am June 2 until 9am June 9, you can treat him to a gift he's sure to use again and again.
Reuters
36 minutes ago
- Reuters
Franc leading Swiss back to deflation vortex, asset stockpiling
LONDON, June 5 (Reuters) - The supercharged Swiss franc is sucking Switzerland back into a deflationary vortex that its central bank will once again struggle to escape, possibly recycling a fresh wave of financial flows back out across the world. The Swiss franc, long perceived as a haven in stressful times, has seen its broad nominal exchange rate index surge 5% since U.S. President Donald Trump's return to the White House. But this is just the latest leg of a relentless appreciation of 20% in five years and 33% over the past decade. In a small open economy, that latest move has been enough to force deflationary relapse and the first drop in annual aggregate Swiss consumer prices in four years last month. In turn, the Swiss National Bank will almost certainly cut its already meagre 0.25% interest rate back to zero this month. A return to the negative interest rate era of the eight years through 2022 now seems almost inevitable further out. Markets already see a one-in-three chance of that happening as soon as the SNB's meeting on June 19. As the last experiment showed, there's a limit to how negative rates can go - mainly because it would be cheaper for big savers to vault their own money than have banks dock more than about 0.75% of deposits annually. And so the SNB may quickly have to resume selling francs and expanding its balance sheet once again to ward off deflation. It's been here before. The SNB's balance sheet ballooned almost 10-fold over the decade to 2022, hitting more than 1 trillion francs ($1.3 trillion) at its peak. While it has shrunk since to 843 billion francs, it remains bigger than annual Swiss GDP and more than four times that of the Federal Reserve's balance sheet as a share of the U.S. economy. Even though the SNB has appeared somewhat reluctant to resume outright franc sales recently, its top brass has pointedly refused to rule out either negative rates or another protracted bout of franc intervention. A sustained reversal of the franc's fortunes may allow the country to dodge the problem of course - with much of this year's franc surge coming against the ebbing dollar, unlike the euro/Swiss rate focus of a decade ago during the euro crisis. But if "safety" flows are at least part of what's driving the Swiss currency higher this year, then it's hard to see trade or geopolitical peace breaking out anytime soon. While this may all feel like deja vu in Switzerland, a slow-motion repeat of the "frankenshock" episode, it speaks to some of the biggest trends impacting markets today and has numerous implications globally. Rebuilding SNB reserves from today's already lofty levels could put upward pressure on a range of euro debt and dollar equity assets. The SNB remains a top 50 shareholder in all seven of the top U.S. big tech megacap stocks, for example, as well as euro zone government debt. The SNB diversified away from the euro in favour of dollars during the euro debt crisis over a decade ago and now holds an equal share of both euro and dollar holdings, as Barclays analysts point out. "A reversal of that trend would not be unprecedented," they said, referring to "jitters" around the prospect of the SNB diversifying away from the dollar in light of recent trade developments. While the SNB's trade-weighted franc index is dominated by a 42% euro weighting, the dollar still commands a 14% share and the dollar, yuan, yen and sterling combined account for about a third of the total. And so a sharp weakening of the dollar, dollar-priced commodities and other dollar-linked currencies still packs a punch for Switzerland regardless of relative stability on the euro. The other complication of a renewed intervention bout is that Switzerland finds itself firmly on the radar of the Trump Treasury's "currency manipulator" report, expected by analysts to be published this month. ING's Francesco Pesole reckons one reason the SNB has been holding off from intervention so far this year is precisely because it wants to avoid being labelled a manipulator by Washington and thus face a more extreme tariff onslaught. Pesole says that with Switzerland already in the "currency manipulator" report's sights due to the country's trade surplus with the U.S., its current account surplus more broadly and its long history of currency capping, the SNB may push negative rates as far as they can go before wading back into foreign exchange markets. "Should the (U.S.) Treasury's FX report be published before then, markets may increase their bets on a 50bp rate cut in June on the view that being added to the monitoring list further reduces the scope for FX interventions," he wrote. Unlike previous franc surges, when FX purchases were the obvious solution, the SNB may now find itself "damned if it does, and damned if it doesn't." The opinions expressed here are those of the author, a columnist for Reuters
